| Protein | Protein Name | Molecular Type | Hallmark | Feature | Evidence | Reference |
|---|
| BCL2 | B-cell CLL/lymphoma 2 | Adaptor Protein | Self-Sufficiency in Growth Signal | Cell Survival | Antisense mediated downregulation of BCL2 inhibits prostate cancer cell survival. | Reference |
| BCL2 | B-cell CLL/lymphoma 2 | Adaptor Protein | Self-Sufficiency in Growth Signal | Cell Survival | BCL2 is involved in prostate cancer cell survival by the regulation of Ceramide and Arachidonate signaling pathway. | Reference |
| BCL2 | B-cell CLL/lymphoma 2 | Adaptor Protein | Cell Death Resistance | Apoptosis Evasion | MicroRNA-15 and MicroRNA-16-1 function as tumor suppressor by targeting BCL2 oncogene and these microRNAs are frequently deleted in prostate cancer | Reference |
| BCL2 | B-cell CLL/lymphoma 2 | Adaptor Protein | Cell Death Resistance | Apoptosis Evasion | MicroRNA-205 is a regulator of anti apoptotic protein BCL2 and is downregulated in prostate cancer | Reference |
| BCL2 | B-cell CLL/lymphoma 2 | Adaptor Protein | Cell Death Resistance | Chemoresistance | It is overexpressed in 70% of androgen independent prostate cancer: contributes to prostate cancer chemoresistance. | Reference |
| BCL2 | B-cell CLL/lymphoma 2 | Adaptor Protein | Androgen Independence | Androgen Independence | BCL2, which is overexpressed in human prostate cancer, plays an important role in the development of androgen independent prostate cancer and currently BCL2 is considered as a therapeutic target in castration resistant prostate cancer. | Reference |